JPRN-jRCT2080221107未知3 期
A randomized, double-blind Phase 3 study of S-474474 in patients with essential hypertension, - Evaluation in non-responder to irbesartan
适应症
试验速览
- 阶段
- 3 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 79age old（—）
- 性别
- All
入选标准
- •Patients with essential hypertension who meet the following criteria:
- •Seated trough systolic blood pressure is not less than140 mmHg, lower than180 mmHg,and seated trough diastolic blood pressure is not less than 90 mmHg, lower than 110 mmHg. etc.
排除标准
- •Patients with renal, hepatic or heart disease
研究者
相似试验
未知
3 期
An open-label Phase 3 study of S-474474 in patients with essential hypertension - Evaluation of the safety and efficacy of long term useHypertensionJPRN-jRCT2080221437SHIONOGI & CO., LTD.
进行中（未招募）
不适用
A Phase 3, randomized, double-blind study of the safety and efficacy of GSK1349572 plus abacavir/lamivudine fixed-dose combination therapy administered once daily compared to Atripla over 96 weeks in HIV-1 infected antiretroviral therapy na?ve adult subjects. - SINGLEHIV-1 infected antiretroviral therapy naive adult subjectsMedDRA version: 9.1Level: LLTClassification code 10008922EUCTR2010-020983-39-ITViiV Healthcare UK Limited800
已完成
3 期
A Phase 3, randomized, double-blind study of the safety and efficacy of GSK1349572 plus abacavir/lamivudine fixed-dose combination therapy administered once daily compared to Atripla over 96 weeks in HIV-1 infected antiretroviral therapy naive adult subjects (ING114467)HIVHIV110047438NL-OMON38393GlaxoSmithKline10
进行中（未招募）
1 期
GSK1349572 plus abacavir/lamivudine fixed-dose combination therapy administered once daily compared to Atripla over 96 weeks in HIV-1 infected adult subjectsHIV-1 infected antiretroviral therapy naive adult subjects.MedDRA version: 14.1Level: LLTClassification code 10008922Term: Chronic infection with HIVSystem Organ Class: 10021881 - Infections and infestationsEUCTR2010-020983-39-DKViiV Healthcare UK Limited800
进行中（未招募）
1 期
A phase 3 clinical trial to compare the safety and effectiveness of GSK1349572 and abacavir/lamivudine compared to Atripla over 96 weeks in patients with HIV infection who have not previously received treatment.EUCTR2010-020983-39-GBViiV Healthcare UK Limited844